EMA — authorised 23 March 2015
- Status: approved
🇪🇺 Kengreal in European Union
EMA authorised Kengreal on 23 March 2015
Marketing authorisations
EMA — authorised 23 March 2015
- Application: EMEA/H/C/003773
- Marketing authorisation holder: Chiesi Farmaceutici S.p.A.
- Local brand name: Kengrexal
- Indication: Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
- Status: approved
Kengreal in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in European Union
Frequently asked questions
Is Kengreal approved in European Union?
Yes. EMA authorised it on 23 March 2015; EMA authorised it on 23 March 2015.
Who is the marketing authorisation holder for Kengreal in European Union?
Chiesi is the originator. The local marketing authorisation holder may differ — check the official source linked above.